Pediatric Hodgkin Consortium trial shows increased complete response rates and reduced radiation therapy use in low-risk patients, suggesting safer treatment options.
In this issue of Blood, Flerlage et al 1 report results from the Pediatric Hodgkin Consortium (PHC) HOD08 trial, where they aimed to reduce the use of radiation therapy (RT) in children with low-risk Hodgkin lymphoma (HL) by increasing chemotherapy dose-density.They demonstrated that a dose-dense modified Stanford V regimen, consisting of vinblastine, doxorubicin, vincristine, bleomycin, mechlorethamine, etoposide, and prednisone led to increased complete response (CR) rates and a reduction in RT use when compared to the predecessor HOD99 trial which utilized less intense VAMP (vinblastine, doxorubicin, methotrexate, and prednisone) chemotherapy.
No takes yet. Share an insight, caveat, or question.
Rosenzweig et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: